SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 22 of 26
Word Count: 1444
Character Count: 8812

Document Content:

be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification. We have entered into agreements with our officers and directors that provide contractual indemnification in addition to the indemnification provided for in our articles of incorporation and amended and restated bylaws. We do not currently carry directors’ and officers’ insurance. However, we may in the future purchase a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

These provisions may discourage
stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect
of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise
benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs
of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

We believe that these provisions
and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

Listing

Shares of our common stock
are listed on the Nasdaq Capital Market under the symbol “SNYR”.

Transfer Agent and Registrar

The transfer agent and registrar
for our common stock is VStock Transfer LLC, 18 Lafayette Place, Woodmere, New York 11598.

PLAN OF DISTRIBUTION

We have entered into a sales agreement with Roth Capital Partners, LLC (the “Lead Agent”) and Bancroft Capital LLC (an “Agent”
and collectively with the Lead Agent, the “Agents”) on November 26, 2025, which we filed as an exhibit to the registration
statement of which this prospectus supplement forms a part. Under the terms of the sales agreement, we may offer and sell up to $5,690,000
of shares of our common stock under this prospectus supplement (the “Offering”), from time to time through or to Roth Capital
Partners and Bancroft Capital LLC, as sales agents or principals. Sales of shares of our common stock, if any, under this prospectus supplement
may be made at market prices and by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under
the Securities Act. We may instruct the Agents not to sell common stock if the sales cannot be effected at or above the price designated
by us from time to time. We or the Agents may suspend the offering of common stock upon notice and subject to other conditions.

The Agents will offer our
common stock subject to the terms and conditions of the sales agreement as agreed upon by us and the Agents. Each time we wish to issue
and sell common stock under the sales agreement, we will notify the Lead Agent of the number or dollar value of shares to be issued, the
time period during which such sales are requested to be made, any limitation on the number of shares that may be sold in one day, any
minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed the Lead
Agent, unless the Lead Agent declines to accept the terms of the notice or we subsequently terminate the placement notice, the Lead Agent
has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and
federal laws and regulations and the rules of Nasdaq, to sell such shares up to the amount specified on such terms. The obligations of
the Agents under the sales agreement to sell our common stock are subject to a number of conditions that we must meet.

We will pay the Lead Agent commissions for its services in acting as agent in the sale of our common stock at a commission rate equal
to 3.0% of the gross sale price per share sold. We estimate that the total expenses for the offering, excluding compensation and reimbursement
payable to the Agents under the sales agreement, will be approximately $235,000. We have also agreed to reimburse the Agents for their
reasonable out-of-pocket expenses, including attorney’s fees, for this Offering, in an amount not to exceed $75,000, in addition
to up to $15,000 per quarterly due diligence update session for the Agents’ counsel’s fees.

Settlement for sales of common
stock will occur on the first business day following the date on which any sales are made, or on some other date that is agreed upon by
us and the Lead Agent in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement
for funds to be received in an escrow, trust or similar arrangement.

In connection with the sale
of the common stock on our behalf, the Agents will be deemed to be underwriters within the meaning of the Securities Act, and their compensation
as sales agents will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution
to the Agents against certain civil liabilities, including liabilities under the Securities Act.

This offering pursuant to
the sales agreement will terminate upon the earlier of (1) the issuance and sale of all shares of our common stock subject to the sales
agreement; and (2) the termination of the sales agreement as permitted therein. We may terminate the sales agreement in our sole discretion
at any time by giving five days’ prior notice to the Agents. The Agents may terminate the sales agreement as to themselves under
the circumstances specified in the sales agreement and in their sole discretion at any time by giving five days’ prior notice to

The Agents and their respective
affiliates have in the past and may in the future provide various investment banking and other financial services for us and our affiliates,
for which services they have received and may in the future receive customary fees.

The prospectus supplement
for the offering in electronic format may be made available on websites maintained by the Agents and the Agents may deliver the prospectus
supplement electronically. To the extent required by Regulation M, the Agents will not engage in any market making activities or stabilizing
activities involving our common stock while the offering is ongoing under this prospectus supplement. This summary of the material provisions
of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed
as an exhibit to the registration statement of which this prospectus supplement forms a part and is incorporated by reference in this
prospectus supplement.

LEGAL MATTERS

The validity of the common
stock offered by this prospectus supplement will be passed upon for us by Nelson Mullins Riley & Scarborough LLP, Raleigh, North
Carolina. Roth Capital Partners, LLC and Bancroft Capital LLC are being represented in connection with this offering by Loeb & Loeb
LLP.

EXPERTS

The consolidated financial
statements of Synergy CHC Corp. as of December 31, 2024 and 2023 and for the years then ended included in this prospectus supplement
have been so included in reliance on the reports of RBSM LLP, an independent registered public accounting firm, which have been incorporated
herein by reference, given on the authority of said firm as experts in auditing and accounting

WHERE YOU CAN FIND MORE INFORMATION

This prospectus supplement
is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information
set forth in the registration statement. Whenever a reference is made in this prospectus supplement to any of our contracts, agreements
or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement
or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement for a copy of such contract,
agreement or other document. Because we are subject to the information and reporting requirements of the Securities Exchange Act of 1934,
as amended, or the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our
SEC filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE